Idel'son L I, Pogorel'skaia E P, Il'in G P, Gorodetskiĭ V M
Ter Arkh. 1984;56(6):93-8.
The authors appraise the efficacy of the treatment of severe aplastic anemia by splenectomy, antilymphocyte globulin and cyclophosphamide. A total of 120 patients were placed under observation. Of these, 103 patients had a severe disease pattern, one hundred and 112 patients with aplastic anemia including 96 with a severe pattern were subjected to splenectomy. Of the 112 splenectomized patients, 78 (69.6%) are alive. Of the 96 patients with severe aplasia, 60 patients (62.5%) are alive. Of 43 deceased patients, 7 had been admitted to the hospital 2-12 days before death and had not been subjected to splenectomy. Three patients died shortly after splenectomy, 8 patients died at the second month after operation. During the first 6 months after operation 20% of the operated patients died, whereupon 10 more per cent of the patients died for 5 months. The patients who survived 10 months may happen to develop a complete or partial remission. Complete remission was attained in 18.8% of the patients, almost complete recovery in 17.7% of the operated, considerable improvement of the estimates was attained in 17.7% of the patients. Antilymphocyte globulin was administered to 23 splenectomized patients. The remission was attained in 6 patients, and 8 more patients improved. If the patients did not respond to the treatment with antilymphocyte globulin, or if they developed relapses, the authors administered cyclophosphamide. Of the 15 patients, 9 responded to the treatment (5 patients improved, remission was attained in 4 patients, 3 of whom are in a state of remission until now). On the 15 patients treated with cyclophosphamide 12 patients have been alive for not less that 2 years.
作者评估了脾切除术、抗淋巴细胞球蛋白和环磷酰胺治疗重型再生障碍性贫血的疗效。共观察了120例患者。其中,103例患者病情严重,112例再生障碍性贫血患者(包括96例病情严重者)接受了脾切除术。在112例接受脾切除术的患者中,78例(69.6%)存活。在96例重型再生障碍性贫血患者中,60例(62.5%)存活。在43例死亡患者中,7例在死亡前2至12天入院,未接受脾切除术。3例患者在脾切除术后不久死亡,8例患者在术后第二个月死亡。术后前6个月,20%的手术患者死亡,随后又有10%的患者在接下来的5个月内死亡。存活10个月的患者可能会出现完全或部分缓解。18.8%的患者实现了完全缓解,17.7%的手术患者几乎完全康复,17.7%的患者病情评估有显著改善。23例接受脾切除术的患者接受了抗淋巴细胞球蛋白治疗。6例患者实现了缓解,另有8例患者病情改善。如果患者对抗淋巴细胞球蛋白治疗无反应或出现复发,作者给予环磷酰胺治疗。在15例患者中,9例对治疗有反应(5例患者病情改善,4例患者实现缓解,其中3例至今仍处于缓解状态)。在接受环磷酰胺治疗的15例患者中,12例患者存活至少2年。